YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
A while ago Coca-Cola (NYSE:KO) reported a quarter where everything moved the right way at once: more cases sold, slightly higher prices, and a wider operating margin. The stock still trades above its own five-year average multiple. The co…
AbbVie ABBV announced that the FDA has granted two Breakthrough Therapy designations (BTDs) to its investigational next-generation antibody-drug conjugate (ADC), telisotuzumab adizutecan (Temab-A; ABBV-400), for two different types of canc…
HMG Strategy Complimentary executive passes remain available for qualified CIOs, CISOs, CTOs, Chief Digital Officers, Chief AI Officers and other senior technology executives FAIRFIELD, Conn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- More than 10…
Bristol Myers Squibb (BMY) said Thursday that a phase 3 study evaluating Zenbexustm in combination w PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
In the EXCALIBER study, results showed a progression-free survival hazard ratio of 0.49 compared with daratumumab, bortezomib and dexamethasone PRINCETON, N.J., October 08, 2026--(BUSINESS WIRE)-- Bristol Myers Squibb Announces ZENBEXUSTM(…
Bristol Myers BMY is banking on key drugs like Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag to drive top-line growth amid a significant decline in legacy drug sales. These key drugs are part of the company's growth portfolio, w…
Redwire Corporation RDW is expanding its microgravity capabilities beyond traditional space infrastructure into pharmaceutical research and development. The company's Pharmaceutical In-Space Laboratory – Bio-crystal Optimization Experiment…
Global leaders share how they are applying decision intelligence to the decisions that run the business MOUNTAIN VIEW, Calif., October 07, 2026--(BUSINESS WIRE)--Aera Technology, the decision intelligence leader, today announced AeraHUB 26…
Bristol-Myers Squibb (BMY) just secured an expanded FDA approval for Camzyos in symptomatic obstructive hypertrophic cardiomyopathy, including eligible pediatric patients. That fresh label update is the starting point for reassessing the s…
New research finds growing prescriber adoption and enthusiasm for TYK2 differentiation, while limited experience, access friction, and questions around joint efficacy temper early launch momentum. Exton, PA, Oct. 06, 2026 (GLOBE NEWSWIRE)…
Radiopharmaceutical development leader brings over two decades of global oncology clinical experience to Lila Bio, including senior roles at RayzeBio and Abdera Therapeutics. SEATTLE, October 06, 2026--(BUSINESS WIRE)--Lila Biologics ("Lil…
For Immediate Release Chicago, IL – October 6, 2026 – Stocks in this week's Dollar General Corp. DG, Bristol-Myers Squibb Co. BMY and Equinor ASA EQNR 3 Stocks with Broker Rating Upgrades Amid Resilient Equity Markets U.S. equities have re…
Bristol-Myers Squibb Company (NYSE:BMY) is in an interesting spot. The company is still one of the biggest names in pharmaceuticals, but its investment story is changing. Some of its older blockbuster drugs are facing patent and generic pr…
Four sessions across two days focusing on key drug discovery and development application areas oforgan-on-a-chip technologies Expert-led presentations and panel discussions featuring leaders across research, regulatory and industry, includ…
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity…
Investing.com -- Shares of Bristol-Myers Squibb Co. (NYSE: BMY) fell 2.5% in premarket trading after Leerink Partners downgraded the pharmaceutical giant from Outperform to Market Perform, citing growing skepticism surrounding key candidat…
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at val…
U.S. equities have remained firmly positive so far this year despite elevated Treasury yields, oil above $100, sticky inflation, tariff uncertainty and narrow market breadth. September's Federal Reserve rate hike tightened financial condit…
Here's an eye-opening statistic: older Americans are more afraid of running out of money than of death itself. And unfortunately, even retirees who have built a nest egg have good reason to be concerned-with the traditional approaches to r…
3 Value Stocks We Steer Clear Of Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they're out of favor. The key risk, however, is that these stocks are usual…
Second-Year Champions in Care Campaign Introduces $1 Million Community Grant Program for Medically Underserved Communities PRINCETON, NJ / ACCESS Newswire / October 5, 2026 / Originally published by Bristol Myers Squibb Bristol Myers Squib…
AbbVie Inc. (NYSE:ABBV) closed at $262.82 on October 2, and Bristol Myers Squibb Company (NYSE:BMY) at $61.15. Both spent the last few years doing the same difficult thing. Replacing a drug that was about to lose its patent with something…
The Trump administration has selected 10 companies, including AbbVie (ABBV [https://seekingalpha.com/symbol/ABBV]), Amgen (AMGN [https://seekingalpha.com/symbol/AMGN]), Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), and GSK (GSK [http…
Agios Pharmaceuticals AGIO is entering an important phase of its growth story as its lead therapy, mitapivat, expands across multiple blood disorders. The drug is marketed as Pyrukynd for pyruvate kinase (PK) deficiency and as Aqvesme for…
Bristol Myers Squibb BMY is banking on label expansion of existing drugs and approval of new drugs to further propel its growth portfolio. Camzyos (mavacamten) is one of the key drugs in this product portfolio. The drug is currently approv…
Second-Year Champions in Care Campaign Introduces $1 Million Community Grant Program for Medically Underserved Communities PRINCETON, N.J., October 01, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the expansion o…
CAMZYOS is the only FDA-approved therapy for the treatment of oHCM in a pediatric population Approval based on positive results of Phase 3 SCOUT-HCM trial, building on the extensive clinical evidence for CAMZYOS in adults with oHCM PRINCET…
[HCM acronym. Hypertrophic Cardiomyopathy concept] Alex Aviles * The US FDA has approved Bristol Myers Squibb's (BMY [https://seekingalpha.com/symbol/BMY]) Camzyos (mavacamten) for children with symptomatic obstructive hypertrophic cardiom…
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks As the Q2 earnings season wraps, let's dig into this quarter's best and worst performers in the pharmaceuticals industry, including Ja…
Investors seeking a high yield and stable fundamentals in the healthcare sector need look no further than Bristol Myers Squibb. Continue Reading
Delta Air Lines CEO Ed Bastian, General Motors President Mark Reuss, Carhartt President and CEO Linda Hubbard, Altria CEO Sal Mancuso, BlackRock's Claire Chamberlain, U.S. Chief Design Officer Joe Gebbia, and leaders from Arist, Boston Dyn…
[Cantor And John Thune Hold Press Conference On Economy] Alex Wong/Getty Images News * The Pharmaceutical Research and Manufacturers of America (PhRMA) has selected former Republican House Majority Leader Eric Cantor as its next CEO and pr…
Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of t…
Company Logo The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding cl…
In September 2026, Bristol Myers Squibb reported first-time, pivotal Phase 3 EXCALIBER-RRMM data showing ZENBEXUS (iberdomide) plus daratumumab and dexamethasone produced a statistically significant, clinically meaningful improvement in mi…
Bristol-Myers Squibb (NYSE:BMY) reported pivotal Phase 3 EXCALIBER-RRMM data for ZENBEXUS in relapsed or refractory multiple myeloma. The Phase 3 trial showed a clinically meaningful advantage in MRD-negative complete response rates versus…